P3.02b-093 Zoledronic Acid Enhances the Effects of Icotinib on Non-Small Cell Lung Cancer Patients with Bone Metastases
نویسندگان
چکیده
منابع مشابه
Clinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran
Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...
متن کاملIntensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer
*KURAに登録されているコンテンツの利用については,著作権法に規定されている私的使用や引用などの範囲内で行ってください。 *著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には,著作権者の許諾を得てください。ただし,著作権者 から著作権等管理事業者(学術著作権協会,日本著作出版権管理システムなど)に権利委託されているコンテンツの利用手続については ,各著作権等管理事業者に確認してください。 Title Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodefic...
متن کاملEffects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for patients with asymptomatic BM remains undefined. A total of 152 patients were identified. 58 patients were excluded. Of the remaining 97 patients, 56 patients received upfront RT followed by icotinib, including WBRT or SRS. 41 p...
متن کاملEfficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.
OBJECTIVE To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC). METHODS A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity. RESULTS A total of 89 patients wer...
متن کاملA Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases
In the pre-tyrosine kinase inhibitors (TKIs) era, non-small cell lung cancer (NSCLC) patients with de novo bone metastases had a worse prognosis than those without. However, whether epidermal growth factor receptor (EGFR)-TKIs affect the outcomes of EGFR mutant NSCLC patients with de novo bone metastases has not been well studied thus far. We retrospectively studied the effect of EGFR mutation ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1760